TWiV 957: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks, changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States, updates on COVID-19–related mortality, impact of community masking on COVID-19, effectiveness of the COVID-19 vaccines against hospitalization with Omicron sub-lineages BA.4 and BA.5 in England, cardiovascular outcomes after Tixagevimab and Cilgavimab use for pre-exposure prophylaxis against COVID-19, how Paxlovid is associated with decreased hospitalization rate among adults with COVID-19, inside the mind of an anti-paxxer, and angiotensin receptor blockers for the treatment of COVID-19. Subscribe (free): Apple Podcasts , Google Podcasts , RSS , email Become a patron of TWiV! Links for this episode Human monkeypox virus infection in women and non-binary individuals (The Lancet) Changes in population immunity against infection and severe disease from variants (Medrxiv) Updates on COVID-19 related mortality (CDC) Impact of community masking on COVID-19 (Science) Effectiveness of the COVID-19 vaccines against hospitalization (The Lancet) Cardiovascular outcomes after tixagevimab and cilgavimab use for pre-exposure prophylaxis (CID) Bebtelovimab fact sheet for providers (FDA) Paxlovid associated with decreased hospitalization among adults (CDC) Inside the mind of an Anti-Paxxer (The Atlantic) Paxlovid patient eligbiliity screening checklist (FDA) Angiotensin receptor blockers for the treatment of COVID-19 (BMJ) Long COVID treatment research study (Stanford) HHS long COVID study ( pdf ) Biden administration requests long COVID fu Contribute to our MicrobeTV fundraiser at PWB Dr. Griffin's treatment guide ( pdf ) Letters read on TWiV 957 Timestamps by Jolene . Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]